Status:
UNKNOWN
Sebum Measurement in Newborn to Detect Hyperexposure to Androgens
Lead Sponsor:
Homerton University Hospital NHS Foundation Trust
Conditions:
Polycystic Ovary Syndrome
Eligibility:
All Genders
30-1 years
Phase:
NA
Brief Summary
The source of PCOS is unknown. Our hypothesis is that over exposure to testosterone of the foetus in utero alters the expression of genes thought to be involved in the cause of PCOS.
Detailed Description
Polycystic ovary syndrome (PCOS) affecting 10-15% of the female population causes excess hair, acne, irregular/absent ovulation, infertility and is associated with hypertension, diabetes, heart attack...
Eligibility Criteria
Inclusion
- Women (with and without a diagnosis of polycystic ovarian syndrome) aged 18-40 with an uncomplicated singleton pregnancy, who deliver a baby at term (37 weeks gestation or longer). Women in the PCOS cohort will be defined by the ESHRE/ASRM Rotterdam criteria. Women with no signs of PCOS who deliver a term baby will serve as the control group.
Exclusion
- Patients who decline consent
Key Trial Info
Start Date :
July 8 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04065100
Start Date
July 8 2019
End Date
December 31 2022
Last Update
June 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Homerton Fertility Centre
London, United Kingdom, E9 6SR